Physician profile
Daniel Theodore Wallis
NPI 1871957076
$9,106.83
in general payments reported to CMS, 2019-2025
32 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $312 · 2021: $78.75 · 2022: $1,615 · 2023: $2,101 · 2024: $2,556 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,913 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,912.75 |
| Education | $187.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,549.38 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $928.71 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $706.48 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $660.11 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $617.10 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $588.73 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $436.13 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $430.99 | 2022-2025 | Adbry, Spevigo, Anzupgo |
| Incyte Corporation | $402.67 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $397.45 | 2022-2025 | |
| Ucb, INC. | $367.78 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $364.97 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $321.89 | 2022-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $221.68 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.91 | 2023-2025 | Spevigo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $140.14 | 2022-2025 | Ilumya |
| Biofrontera INC. | $135.92 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $107.86 | 2022-2025 | Oracea, Aklief, Twyneo |
| Genentech USA, INC. | $86.18 | 2020 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Merz North America, INC. | $71.63 | 2024 | |
| Kyowa Kirin, INC. | $54.84 | 2024 | Poteligeo |
| Janssen Scientific Affairs, LLC | $40.36 | 2022 | |
| Revance Therapeutics, INC. | $26.65 | 2025 | Daxxify |
| Krystal Biotech INC | $26.06 | 2024 | Vyjuvek |
| Integra Lifesciences Corporation | $24.42 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Epi Health, LLC | $23.28 | 2022 | |
| Fresenius Kabi USA, LLC | $22.45 | 2023 | Idacio |
| Sandoz INC. | $22.44 | 2023 | Hyrimoz |
| Mayne Pharma Commercial LLC | $19.01 | 2022 | |
| Fidia Pharma USA INC. | $16.66 | 2025 | |
| Strata Skin Sciences, INC. | $14.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wallis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.